{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=55&state=Pennsylvania",
    "query": {
      "state": "Pennsylvania",
      "city": "Philadelphia",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 17147,
    "total_pages": 1715,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=56&state=Pennsylvania&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=54&state=Pennsylvania&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T17:00:01.082Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00300196",
      "title": "ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke",
        "Cerebral Ischemia",
        "Brain Infarction"
      ],
      "interventions": [
        {
          "name": "Ancrod (Viprinex)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Neurobiological Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2006-03",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2010-01-12",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 39,
      "location_summary": "Chico, California • Fresno, California • La Mesa, California + 32 more",
      "locations": [
        {
          "city": "Chico",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300196"
    },
    {
      "nct_id": "NCT00002070",
      "title": "Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Sargramostim",
          "type": "DRUG"
        },
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Schering-Plough",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002070"
    },
    {
      "nct_id": "NCT00068770",
      "title": "Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2003-10",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 7,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068770"
    },
    {
      "nct_id": "NCT02079883",
      "title": "Ocriplasmin Research to Better Inform Treatment (ORBIT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Symptomatic Vitreomacular Adhesion"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "ThromboGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2014-05",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-21",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 110,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Encino, California + 92 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079883"
    },
    {
      "nct_id": "NCT01158820",
      "title": "Alternative Sedation During Bronchoscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sedation"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine load",
          "type": "DRUG"
        },
        {
          "name": "Ketamine load",
          "type": "DRUG"
        },
        {
          "name": "Midazolam load",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl load",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine maintenance",
          "type": "DRUG"
        },
        {
          "name": "Ketamine maintenance",
          "type": "DRUG"
        },
        {
          "name": "Midazolam demand",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl demand",
          "type": "DRUG"
        },
        {
          "name": "Benadryl demand",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2010-06",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158820"
    },
    {
      "nct_id": "NCT07804186",
      "title": "Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "Darovasertib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib (Xalkori)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2026-09-04",
      "completion_date": "2034-04",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07804186"
    },
    {
      "nct_id": "NCT03876769",
      "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CTL019",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 121,
      "start_date": "2019-06-24",
      "completion_date": "2027-10-19",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876769"
    },
    {
      "nct_id": "NCT07115329",
      "title": "A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Zelquistinel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndeio Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 164,
      "start_date": "2026-01-05",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07115329"
    },
    {
      "nct_id": "NCT05145127",
      "title": "Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "PF-06741086",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "74 Years",
        "sex": "MALE",
        "summary": "1 Year to 74 Years · Male only"
      },
      "enrollment_count": 245,
      "start_date": "2021-11-17",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 4,
      "location_summary": "Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145127"
    },
    {
      "nct_id": "NCT05528861",
      "title": "A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Lirentelimab (AK002)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Allakos Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2022-10-26",
      "completion_date": "2024-04-18",
      "has_results": true,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-11-19T17:00:01.082Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528861"
    }
  ]
}